AXIM BIOTECHNOLOGIES, INC.
AXIM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AXIM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AXIM
AXIM Biotechnologies is an early-stage biotechnology company developing product candidates including SPX-009 and diagnostic tests, with no current revenue and a history of operating losses.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2024.
Tracking 1 clinical trial · 1 catalyst for AXIM BIOTECHNOLOGIES, INC..
AXIM Biotechnologies is an early-stage biotechnology company developing product candidates including SPX-009 and diagnostic tests, with no current revenue and a history of operating losses.
- AXIM Biotechnologies is in early stages of development with no established sales or earnings [sec_mda · as of 2023-05-22].
- As of June 30, 2022, the company had cash and cash equivalents of $65,163 and an accumulated deficit of $61,191,579 [sec_mda · as of 2022-08-16].
- The company has two FDA-cleared diagnostic tests for dry eye disease and is developing SPX-009 and COVID-19 product candidates [sec · filed 2022-07-25].
- AXIM expects G&A expenses of approximately $3,500,000 for 2023 and does not expect R&D expenditures to exceed $2 million in 2023 [sec_mda · as of 2023-05-22].
- The company faces significant risks including the need for additional capital, regulatory approvals, and competition [sec · filed 2022-07-25].
What works
- AXIM has two FDA-cleared diagnostic tests for dry eye disease, providing a commercial foothold [sec · filed 2022-07-25].
- The company is advancing SPX-009 and COVID-19 product candidates, which could address unmet medical needs [sec · filed 2022-07-25].
What to weigh
- AXIM has no established revenue and has incurred operating losses since inception, with an accumulated deficit of $61.2 million as of June 30, 2022 [sec_mda · as of 2022-08-16].
- The company has very limited cash ($65,163 as of June 30, 2022) and a working capital deficit, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2022-08-16].
- AXIM's product candidates require significant additional research, clinical trials, and regulatory approval before commercialization, with no guarantee of success [sec · filed 2022-07-25].
- The company is dependent on future financing, which may not be available on acceptable terms, and faces intense competition from other pharmaceutical and biotechnology companies [sec · filed 2022-07-25].
From the filings
Quoted directly from source documents.
AXIM is in early development stages with no sales or earnings.
“We are in our early stages of development and growth, without established records of sales or earnings.”
SEC MD&A · May 22, 2023
AXIM has two FDA-cleared diagnostic tests for dry eye disease.
“the commercial acceptance of our two FDA cleared diagnostic tests for dye eye disease”
SEC filings · July 25, 2022
AXIM's cash position and accumulated deficit as of June 30, 2022.
“As of June 30, 2022, we had cash and cash equivalents of $65,163, working capital deficit of $2,538,329, and an accumulated deficit of $61,191,579.”
SEC MD&A · August 16, 2022
AXIM expects R&D expenditures not to exceed $2 million in 2023.
“We do not expect R&D expenditures to exceed $2 million i”
SEC MD&A · August 16, 2022
Catalyst timeline
- 2028-07-01 · Phase3_Topline — Topline results from a Phase III randomized trial of steroids + tyrosine kinase inhibitor (TKI) induction with chemotherapy are expected.
Risks & what to watch (4)›
Key risks
- Going concern risk — Very low cash and working capital deficit raise substantial doubt about ability to continue operations [sec_mda · as of 2022-08-16].
- Regulatory and clinical risk — Product candidates require extensive clinical trials and regulatory approval, with no guarantee of success [sec · filed 2022-07-25].
- Financing risk — Future capital needs depend on uncertain financing; may not be available on favorable terms [sec · filed 2022-07-25].
- Competition risk — Operates in a rapidly changing environment with substantial competition from other biotech firms [sec · filed 2021-05-14].
What to watch
- Ability to secure additional financing to fund operations and clinical trials [sec · filed 2022-07-25].
- Progress of SPX-009 and COVID-19 product candidates through preclinical and clinical development [sec · filed 2022-07-25].
- Commercial adoption of FDA-cleared diagnostic tests for dry eye disease [sec · filed 2022-07-25].
- Regulatory updates and potential approvals for product candidates [sec · filed 2022-07-25].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run AXIM BIOTECHNOLOGIES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AXIM BIOTECHNOLOGIES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.1 months
OCF -$262K · Net income -$2M
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~671d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for AXIM BIOTECHNOLOGIES, INC.?
AXIM Biotechnologies is an early-stage biotechnology company developing product candidates including SPX-009 and diagnostic tests, with no current revenue and a history of operating losses.
What is AXIM BIOTECHNOLOGIES, INC.'s next catalyst?
AXIM BIOTECHNOLOGIES, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemothera" — expected July 1, 2028.
Who is the CEO of AXIM BIOTECHNOLOGIES, INC.?
Ms. Catalina Valencia J.D. is the chief executive officer of AXIM BIOTECHNOLOGIES, INC. (AXIM).
Where is AXIM BIOTECHNOLOGIES, INC. headquartered?
AXIM BIOTECHNOLOGIES, INC. (AXIM) is headquartered in San Diego, CA, United States.
What therapeutic areas does AXIM BIOTECHNOLOGIES, INC. focus on?
AXIM BIOTECHNOLOGIES, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.